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Introduction
The epidemic of type 2 diabetes is a growing public health problem that threatens to reduce life expectancy and increase 
morbidity as a result of its complications. Hyperglycemia, 
the cardinal feature of diabetes, can be controlled either by 
the exogenous administration of insulin or through oral anti-
diabetic drugs which increase insulin secretion, improve insulin 
sensitivity or reduce glucose absorption from the gastrointestinal 
tract.  In spite of advances in therapy, the debilitating vascular 
complications of diabetes continue to occur.1-3 One of the major 
reasons for this is the lack of awareness among patients regarding 
the seriousness of diabetes and consequences of poor control. 
According to the Chennai Urban Rural Epidemiology Study 
(CURES) study, awareness and knowledge regarding diabetes 
is still grossly inadequate in India.4 The CURES illustrates that 
the “rule of halves” described in hypertension is also valid for 
diabetes in India 4 as summarized in Figure 1.
Complications of Diabetes
The complications of diabetes represent clinically definable 
endpoints that seem to occur as a result of a series of complex 
intracellular pathways. These pathways are not fully understood 
at present, but may act alone or in unison to trigger adverse 
effects in multiple organs.5 The clinical endpoints are long 
term vascular complications which are classified as being 
either “macrovascular” (for example, heart disease, stroke, and 
peripheral vascular disease [which can lead to ulcers, gangrene, 
and amputation]) or “microvascular” (for example, retinopathy, 
nephropathy and neuropathy). In spite of the availability of 
newer and more effective agents to treat diabetes, the various 
complications of diabetes continue to represent the major cause 
of morbidity and mortality in these patients.1-3, 6-10 
The Diabcare-Asia observational study showed that type 
2 diabetes begins at an early age amongst Indians.11 With 
increasing duration of diabetes, glycemic control deteriorates, 
leading to late complications. Diabetes care in India leaves 
much to be desired and concerted efforts to increase awareness 
amongst health professionals to improve diabetes care are 
urgently needed.12,13
Prevention of Diabetes Complications-
Clinical Evidence from Landmark 
Trials
The benefits of tight glycemic control in preventing chronic 
diabetic complications remained debated upto the mid 1990’s. 
One of the seminal studies which confirmed the importance of 
optimizing glycemic control in type 1 diabetes, was the Diabetes 
Control and Complications Trial (DCCT),14 and its follow-up 
observational study, the Epidemiology of Diabetes Intervention 
and Complications (EDIC) study,15 The conclusions of the DCCT 
and EDIC studies were similar to those of the much smaller 
studies, as summarized in a meta-analysis and showed that good 
control of diabetes can prevent microvascular complications.16 
Other studies have explored the issue of intensive blood glucose 
control in patients with type 2 diabetes and have also addressed 
whether other therapeutic options such as blood pressure 
reduction and/or lipid lowering can act in concert with improved 
glycemic control to reduce the incidence and progression 
of vascular complications particularly the macrovascular 
complications. These studies include the Multifactorial 
Intervention Steno-2 study,17 the United Kingdom Prospective 
Diabetes Study (UKPDS),18 the Action in Diabetes and Vascular 
Disease: PreterAx and Diamicron modified release Controlled 
Evaluation (ADVANCE) study,19, 20 the Veterans Affairs Diabetes 
Trial (VADT),21 and the Action to Control Cardiovascular Risk 
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Fig. 1 : Rule of halves in diabetes
 
Known
diabetes
(33.0%)
Uncontrolled 
diabetes  71.0%
 
Non-diabetic
subjects
(84.0%)
Mohan V  et al,  J Assoc Physicians India. 53: 283 – 287, 2005
Under 
control 29.0% 
(5.9% of total 
diabetic subjects)
Diabetes 
under control:
Undiagnosed
diabetes
(68.0%) n=26,001
No
treatment
44.0%
No
treatment
56.0%
Diabetes
(16.0%)
© SUPPLEMENT TO JAPI • APrIL 2011 • VOL. 59    9
in Diabetes (ACCORD) study.22 The phenomenon of ongoing 
beneficial effects on diabetic complications after a period 
of improved glycemic control followed by a return to usual 
(often poorer) metabolic control was described as representing 
“metabolic memory” by the DCCT/EDIC investigators and as 
the “legacy effect” by the UKPDS investigators.23 
In the DCCT, type 1 diabetes patients were either placed on 
standard or intensive treatment regimens to normalize their 
glucose levels. Because the occurrence as well as progression 
of microvascular complications viz, retinopathy, nephropathy 
and neuropathy was profoundly reduced in patients with tight 
glucose control, the DCCT was prematurely terminated after a 
mean time of 6.5 years with a recommendation that all patients 
be given intensive therapy.14
Epidemiology of Diabetes 
Intervention and Complications 
(EDIC) study 
The EDIC trial, a follow-up to the DCCT, showed that 
compared to their counterparts who had earlier received 
intensive therapy, patients on the standard treatment regimen 
during the DCCT continued to have a higher incidence of 
complications several years later, although the glycated 
hemoglobin of both groups had now become similar. This 
suggests that the benefits of early tight control persist for several 
years even if the control is relaxed.  Besides, new data from EDIC 
also suggests that the influence of early glycemic control on the 
progression to macrovascular events also may become more 
evident on longer follow-up.24-27 
The first DCCT follow-up showed that the risk of retinopathy 
remained significantly reduced in the intensive group compared 
to the conventional treatment group in the first four years after 
the end of the trial, despite similar HbA1C levels over this 
period.28 More convincing results were obtained after 10 years 
of EDIC follow-up, in which the HbA1C levels had converged 
completely and the follow-up was longer. The intensive 
treatment group had lower rates of progression of retinopathy 
and proliferative retinopathy but the risk reductions at 10 years 
were lower compared to the first 4 years of follow-up.29 Diabetic 
nephropathy was reported during the 8 years’ follow-up and 
showed a reduction in new microalbuminuria and clinical 
albuminuria, with fewer cases of hypertension and patients 
needing renal replacement therapy, in the former intensively 
treated group.30 
Diabetic neuropathy was also reported at 8 years’ follow-up 
with a reduction in neuropathic symptoms and signs in the 
former intensively treated group.31 During the 17 years of 
follow-up in DCCT and EDIC, intensive therapy reduced the 
risk of any cardiovascular disease and the risk of non-fatal 
myocardial infarction, stroke, or death from cardiovascular 
disease.32 A beneficial effect of former intensive diabetic control 
was noted on coronary artery calcification at 7 to 9 years’ follow-
up. In the EDIC study after 6 years of follow up the progression 
of carotid artery intima–media thickening was less in the former 
intensively treated group.33 
Table 1 shows the reduction in various complications in the 
former intensive treatment group in the EDIC study.
Collectively, these observations support the concept that early 
glycemic environment is imprinted on the tissues and vascular 
cells and the authors of the DCCT/EDIC have referred to this 
phenomenon as “metabolic memory”.26
Clinical Evidence from the UKPDS 
Data from the United Kingdom Prospective Diabetes Study 
(UKPDS) ratifies this evidence in subjects with type 2 diabetes. 
Specifically, people with lower fasting plasma glucose values 
at the time of diagnosis had fewer vascular complications and 
fewer adverse clinical outcomes over time as compared to people 
with higher fasting plasma glucose values, despite similar rates 
of glycemia later,25 suggesting that early metabolic control has 
enduring beneficial effects even in type 2 diabetes. 
In the UKPDS, patients with type 2 diabetes mellitus who were 
on intensive glycemic control had a lower risk of microvascular 
complications than those receiving conventional dietary therapy. 
A post-trial monitoring was done to determine whether this 
improved glucose control persisted and whether such therapy 
had a long-term effect on macrovascular outcomes.27 In this 
Outcomes Study, of 5102 patients with newly diagnosed type 
2 diabetes, 4209 were randomly assigned to receive either 
conventional therapy (dietary restriction) or intensive therapy 
(either sulfonylurea or insulin or, in overweight patients, 
metformin) for glucose control. In the post-trial monitoring, 
3277 patients were asked to attend the UKPDS clinics annually 
for 5 years, but no attempts were made to maintain their 
previously assigned therapies. Annual questionnaires were 
used to follow patients who were unable to attend the clinics. All 
patients in years 6 to 10 of follow up were also assessed through 
questionnaires. Seven prespecified aggregate clinical outcomes 
from the UKPDS were examined on an intention-to-treat basis, 
according to previous randomization categories. After the first 
year, between-group differences in glycated hemoglobin levels 
were lost. In the sulfonylurea–insulin group, relative reductions 
in risk persisted at 10 years, for any diabetes-related endpoint 
(9%, p = 0.04), for microvascular disease (24%, p = 0.001), for 
myocardial infarction (15%, p = 0.01) and for death from any 
cause (13%, p = 0.007). In the metformin group, significant risk 
reductions persisted for any diabetes-related endpoint (21%, p 
= 0.01), myocardial infarction (33%, p = 0.005), and death from 
any cause (27%, p = 0.002). Thus it was concluded that despite 
an early loss of glycemic differences, a continued reduction in 
microvascular risk and emergent risk reductions for myocardial 
infarction and death from any cause were observed during the 10 
Table 1 : Epidemiology of Diabetes Intervention and 
Complications (EDIC) study: Key findings
Complication  
(years of follow up)
% reduction in former intensive 
treatment group
Retinopathy (10 years EDIC)
Progression of retinopathy 24
Progression to Proliferative 
retinopathy 
59
Nephropathy (8 years EDIC)
New microalbuminuria 59
Clinical albuminuria 84
Neuropathy (8 years EDIC)
Symptoms 51
Signs 43
Cardiovascular disease (17 years DCCT+EDIC)
Any 42
Non-fatal myocardial infarct, 
stroke or CVD death
57
CVD = cardiovascular disease; 
DCCT = Diabetes Control and Complications Trial
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years of post-trial follow-up. A continued benefit after metformin 
therapy was evident among overweight patients. The beneficial 
effect of early intensive control on subsequent development of 
diabetes complications has been termed as the “legacy effect” 
by the UKPDS group.
Mechanisms for “Metabolic Memory” 
and “Legacy Effect”
Two current hypotheses suggest that poor control of diabetes 
results in some irreversible mitochondrial or vascular change 
which then predisposes or progresses to overt long-term 
complications. To what extent the cause of the damage is 
glucotoxicity or lipotoxicity or a combination of these factors 
is unknown and no doubt these toxic effects are modified by 
other inherited or acquired metabolic processes. The well-
established time relationship of duration of diabetes and 
incidence of long-term complications is therefore shifted to 
the left by poor metabolic control. For most patients with 
type 1 diabetes, HbA1C measurements are the only evidence 
available of their overall control as mitochondrial function or 
detailed vascular health are not easily or routinely assessed 
– and indeed, if irreversible, not particularly helpful for the 
individual. Perhaps, carotid artery intimal thickness or vascular 
reactivity and resistance should be measured and followed to 
help identify vascular risk in patients. The accumulation of 
AGEs, which are formed during periods of hyperglycemia and 
persist for many years, may be one of the important factors in 
metabolic memory. AGEs are a heterogenous group of chemical 
moieties occurring as a result of a nonenzymatic reaction of 
glucose with proteins, lipids, and nucleic acids. The role of 
AGEs in the progression and complications of diabetes has been 
reviewed recently 34. AGEs act directly to induce cross-linking 
of long-lived proteins such as collagen to promote vascular 
stiffness, and, thus, alter vascular structure and function. AGEs 
can also interact with certain receptors, to induce intracellular 
signalling that leads to enhanced oxidative stress and elaboration 
of key proinflammatory and prosclerotic cytokines. AGE 
modification of mitochondrial proteins may be irreversible and 
may result in decline of mitochondrial function with excess 
formation of reactive oxygen species. Support for the concept 
of the deleterious effects of the accumulation of AGEs (glycated 
collagen and carboxymethyllysine) has been obtained from skin 
biopsies in the DCCT and the EDIC study with the prediction 
of risk of progression of retinopathy and nephropathy, even 
after adjustments for mean HbA1C. Indeed the predictive effect 
of HbA1C was abolished after adjustment for the two AGEs 
measured.35, 36
Other theories on the mechanisms of metabolic memory have 
been reviewed recently and include the idea that oxidative stress 
persists after normalisation of glucose levels and that there is 
long-lasting activation of epigenetic changes in the promoter 
region of a key inflammatory marker by transient spikes of 
hyperglycemia in mice.  Another theory holds that insulin in 
addition to suppressing glucotoxicity and lipotoxicity also has 
important anti-inflammatory effects. Figure 2 summarizes the 
vicious cycle of metabolic memory.37
 “Clinical Inertia” in Diabetes – 
Failure to Achieve Tight Control and 
the Concept of “Avoidable Glycemic 
Burden”
Type 2 diabetes is a progressive disease. The two main 
pathophysiologies in type 2 diabetes are insulin resistance and 
beta-cell secretory defect. Although IR has long been considered 
to be the initial pathophysiological derangement in type 2 
diabetes, evidence is accumulating that beta-cell dysfunction 
may start earlier in the course of the disease than was initially 
believed. The UKPDS showed that by the time diabetes was 
diagnosed, patients had already lost more than 50% of their 
beta-cell secretory capacity, and this beta cell loss continues 
inexorably as time passes. 
The conventional approach to treatment of type 2 diabetes 
follows a step-wise strategy. This involves sequential introduction 
of lifestyle modification, single oral antidiabetic agents then, oral 
antidiabetic agents in combination and finally insulin therapy. 
Often there is a long delay before a new agent is introduced, 
even though the HbA1C levels are way above target. This 
failure to initiate or intensify treatment even when indicated 
is termed “clinical inertia”. As a result of clinical inertia, 
patients accumulate several years of hyperglycemia before 
therapy is intensified or changed- the so-called “avoidable 
glycemic burden”. It has been estimated that an average patient 
accumulates 5 years of HbA1C more than 8%, and 10 years of 
HbA1C more than 7% before insulin therapy is initiated.38
Clinical inertia in achieving glycemic targets in Indian 
diabetic subjects could be expected to be even more due to 
the low rates of awareness of diabetes and its complications in 
India.12 Moreover, other factors like non-affordability, lack of 
accessibility to health care services, and inadequate follow-up 
are additional factors contributing to this problem in developing 
countries like India. 
Benefits of Early Insulin Therapy
The currently available oral antidiabetic agents have 
different mechanisms of action. However, all of them exert their 
antihyperglycemic effects only if some degree of endogenous 
insulin is present. As beta cell function declines with increasing 
duration of diabetes, these agents ultimately become ineffective, 
even in combination. To date, no antidiabetic agent has been 
shown to arrest or reverse beta cell decline indefinitely in type 
2 diabetes. Therefore, most patients with type 2 diabetes will 
ultimately need insulin to achieve their glycemic targets. 
Insulin is the antidiabetic agent par excellence. It has a proven 
safety record stretching back to the 1920s. The dosage of insulin 
is limited only by hypoglycemia; it is safe in renal, hepatic and 
cardiac disease and in pregnancy. Used correctly, it can bring 
any level of elevated HbA1C to target.
In addition to its beneficial effects on cardiovascular risk 
factors such as cholesterol, triglycerides and waist-hip ratios, 
Fig. 2 : The  vicious circle of metabolic memory
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insulin therapy also appears to partially restore insulin-mediated 
endothelial function,40 improve vasodilatation41 and fibrinolytic 
profiles.42
Insulin therapy also has the ability to reverse glucotoxicity- 
the temporary decline in beta cell function following chronic 
exposure to high glucose concentrations. Intensive insulin 
therapy has been shown to significantly improve beta cell 
function in patients who have failed maximal doses of oral 
antidiabetic agents. Also, short courses of insulin therapy 
administered early in the course of type 2 diabetes have been 
shown to induce temporary “remission” of diabetes, during 
which time diabetes can be controlled with diet alone.39 Such 
early use of insulin has also been shown to improve beta cell 
function.43
There are numerous barriers to initiating insulin in 
clinical practice. Patients as well as physicians have several 
misconceptions regarding insulin, most of which are not 
supported by hard evidence. The most common concerns relate 
to weight gain, hypoglycemia and the fear of injections.  While 
weight gain is frequent with insulin injections, the long-term 
benefits of tight glycemic control far outweigh the minor risks 
associated with this. Moreover, many of the currently available 
oral antidiabetic agents are also not free of this side-effect. Newer 
insulin preparations have less tendency to cause weight gain 
compared to conventional insulins.44
Hypoglycemia is the major factor preventing patients with 
diabetes from achieving glycemic targets. The incidence of severe 
hypoglycemia is thankfully low in type 2 diabetes patients, even 
if they are on insulin. The risk of hypoglycemia can be minimized 
by using proper insulin regimens, patient education, regular 
monitoring and by the use of newer insulin analogues, which 
have a more physiological time-action profile. 
The advent of newer insulin delivery devices like insulin 
pens and finer needles has made the administration of insulin 
a less painful affair. Proper attention to injection technique can 
also minimize the pain associated with insulin injections. Use 
of Continuous Subcutaneous Insulin Infusion pump enables the 
patient to derive the full benefits from intensive insulin therapy 
with minimum disruption to his lifestyle and achieve excellent 
control, although it is currently quite expensive.
In spite of the advances in insulin pharmacology and delivery 
systems, insulin use is often delayed until it is absolutely 
necessary. To improve diabetes management and glycemic 
control nationwide, physicians must learn to overcome clinical 
inertia, to intensify therapy when appropriate, and to use insulin 
when clinically indicated. From an intervention point of view, 
many strategies might be developed to reduce clinical inertia 
and its determinants. Educational or learning interventions that 
target cognitive barriers to medication initiation or intensification 
for patients with chronic disease have received some attention 
and initial reports show some positive effects on clinical inertia. 
Patient empowerment might also decrease clinical inertia, 
and some previous studies have demonstrated that patient 
empowerment leads to better diabetes care.45
Conclusions
Early, intensive treatment of new onset diabetes mellitus 
aimed at tight glucose control reduces the risk of microvascular 
complications and probably, macrovascular disease as well. 
“Metabolic memory” and “legacy effect” are terms that have 
been used to describe the fact that glucose control early in the 
natural history of diabetes profoundly influences the prognosis 
later on in life. Most patients with type 2 diabetes ultimately 
require insulin to attain glycemic targets. Early use of   insulin 
therapy can help normalize blood sugar and HbA1C levels and 
thus enable patients to benefit from a favourable “metabolic 
memory” or “legacy effect”. While there are several barriers 
to initiation of insulin therapy, most of these can be overcome 
by patient education and judicious use of new technology like 
newer insulins and insulin delivery devices.
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